All In Biotech

NDA 202736 · Arbor Pharms LLC

Sklice

Ivermectin · Topical · Antiparasitic; Pediculicide

Last checked: Nov 19, 2026Latest source record: May 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Feb 7, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

221

83 Phase 3, 9 recruiting

FAERS reports

3,499

1,942 serious, 329 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 11, 2024.

Use treats head lice

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SKLICE · IVERMECTIN 0.5% · LOTION, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Ivermectin" as an intervention, any sponsor and status, largest first.

All 221 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective644
  • off label use403
  • product use in unapproved indication286
  • pruritus172
  • headache165
  • fatigue125
  • asthenia121
  • nausea115
  • pyrexia113
  • diarrhoea102
  • strongyloidiasis102
  • vomiting102

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20056
20063
20073
20087
200912
20103
201111
20126
201361
201465
201560
201647
2017212
2018269
2019219
2020201
2021387
2022350
2023295
2024326
2025525
2026431

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 833 on PubMed

Sponsor: Arbor Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.